LENZ LENZ Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: LENZ

Price (delayed)

$7.22

Market cap

$226.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.64

Enterprise value

$201.84M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 21

graphite bio is a next-generation gene editing company focused on the development of first-in-class therapies for patients suffering from life-threatening genetic diseases. the company’s platform harnesses the natural cellular process ...

Highlights
LENZ Therapeutics's debt has shrunk by 65% YoY and by 32% QoQ
The revenue is up by 10% since the previous quarter
The equity is up by 28% year-on-year but it has declined by 13% since the previous quarter
The company's net income has shrunk by 128% YoY and by 33% QoQ
The EPS has plunged by 112% YoY and by 28% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://graphitebio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LENZ

LENZ stock price

How has the LENZ Therapeutics stock price performed over time
Intraday
3%
1 week
-9.64%
1 month
-22.2%
1 year
-75.27%
YTD
-54.88%
QTD
-21.09%

Financial performance

How have LENZ Therapeutics's revenue and profit performed over time
Revenue
$20.99M
Gross profit
$19.5M
Operating income
-$118.34M
Net income
-$109M
Gross margin
92.9%
Net margin
-519.3%
The company's net income has shrunk by 128% YoY and by 33% QoQ
LENZ's operating income has dropped by 99% year-on-year and by 30% since the previous quarter
LENZ Therapeutics's net margin has decreased by 21% QoQ
LENZ's operating margin is down by 18% since the previous quarter

Price vs fundamentals

How does LENZ's price correlate with its fundamentals

Growth

What is LENZ Therapeutics's growth rate over time

Valuation

What is LENZ Therapeutics stock price valuation
P/E
N/A
P/B
0.92
P/S
10.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.62
The EPS has plunged by 112% YoY and by 28% from the previous quarter
The stock's price to book (P/B) is 74% less than its last 4 quarters average of 3.4 and 58% less than its 5-year quarterly average of 2.1
The equity is up by 28% year-on-year but it has declined by 13% since the previous quarter
The stock's price to sales (P/S) is 85% less than its last 4 quarters average of 69.6
The revenue is up by 10% since the previous quarter

Efficiency

How efficient is LENZ Therapeutics business performance
LENZ Therapeutics's ROE has plunged by 97% YoY and by 25% from the previous quarter
LENZ's return on assets has dropped by 92% year-on-year and by 23% since the previous quarter
The return on invested capital has dropped by 78% year-on-year and by 25% since the previous quarter
The ROS has contracted by 21% from the previous quarter

Dividends

What is LENZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LENZ.

Financial health

How did LENZ Therapeutics financials performed over time
LENZ's total liabilities has soared by 182% year-on-year and by 21% since the previous quarter
LENZ Therapeutics's quick ratio has plunged by 56% YoY and by 27% from the previous quarter
LENZ Therapeutics's debt is 100% lower than its equity
LENZ Therapeutics's debt has shrunk by 65% YoY and by 32% QoQ
The equity is up by 28% year-on-year but it has declined by 13% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.